Medicine and Dentistry
Cell-Free DNA
98%
Circulating Tumor DNA
93%
Circulating Tumor Cell
65%
Aneuploidy
51%
Prostate Cancer
46%
Neoplasm
41%
Biological Marker
38%
Liquid Biopsy
37%
Next Generation Sequencing
32%
Disease Exacerbation
29%
Breast Cancer
28%
Chemoradiotherapy
28%
Overall Survival
26%
Cabazitaxel
25%
Castration Resistant Prostate Cancer
25%
Esophageal Cancer
23%
False Positive Result
23%
Hepatocellular Carcinoma
23%
Progression Free Survival
23%
Hematopoiesis
23%
Bevacizumab
23%
Paclitaxel
23%
Metastatic Melanoma
23%
PARP Inhibitor
23%
Ovarian Cancer
23%
Esophageal Cancer
23%
Carcinogenesis
23%
DNA Methylation
17%
DNA Determination
17%
Exome
15%
DNA Sequence
15%
Krukenberg Tumor
15%
Screening Test
13%
Leukapheresis
12%
Exon
11%
Gene Frequency
10%
Minimal Residual Disease
10%
Methylation
10%
Tumor Biopsy
10%
Biopsy Technique
8%
Arm
7%
Esophagus Carcinoma
7%
Specific Tumor
7%
Exome Sequencing
7%
Identified Patient
7%
Patient Experience
7%
Maintenance Therapy
7%
DNA Mismatch Repair
7%
Therapy Resistance
7%
Blood Cell
7%
Biochemistry, Genetics and Molecular Biology
Circulating Tumor DNA
100%
Next Generation Sequencing
60%
Blood Plasma
46%
Aneuploidy
43%
Genomics
25%
Germline
23%
Germ Cell
23%
Poly ADP Ribose Polymerase
23%
Epigenetics
23%
Differentially Methylated Regions
23%
Leukapheresis
23%
Exon
23%
Carcinogenesis
23%
Progression Free Survival
23%
Bevacizumab
23%
Gene Frequency
21%
RNA
19%
Overall Survival
19%
DNA Methylation
16%
Tumor Volume
16%
Dynamics
15%
DNA Sequence
11%
Exome
11%
Phosphatidylinositol-4,5-bisphosphate 3-Kinase
11%
Alpha Chain
11%
Genomic Structural Variation
11%
Enzyme Active Site
11%
Wild Type
11%
Amplicon
11%
Cancer Genome Sequencing
11%
Screening Test
11%
Methylation
10%
Flow Cytometry
9%
DNA Mutation
9%
Messenger RNA
6%
Tumor Suppressor Gene
5%
Exome Sequencing
5%
DNA Mismatch Repair
5%
Hemocyte
5%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
74%
Aneuploidy
49%
Prostate Cancer
46%
Biological Marker
37%
Overall Survival
26%
Cabazitaxel
25%
Castration Resistant Prostate Cancer
25%
Circulating Tumor DNA
24%
Paclitaxel
23%
Progression Free Survival
23%
Breast Cancer
23%
Bevacizumab
23%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
23%
Ovary Cancer
23%
Disease Exacerbation
23%
Metastatic Melanoma
23%
Chemotherapy
19%
Ovary Carcinoma
15%
Taxane
15%
Therapy Resistance
7%
Enzalutamide
6%
Abiraterone
6%
Docetaxel
6%